<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437812</url>
  </required_header>
  <id_info>
    <org_study_id>GOA-TCOM1</org_study_id>
    <nct_id>NCT02437812</nct_id>
  </id_info>
  <brief_title>Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma</brief_title>
  <official_title>A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Initially, the prospect of metformin as a neoplastic treatment was considered for
      malignancies of the prostate, colon and pancreas. However, only select clinical studies
      involving the use of metformin in the treatment of ovarian cancer have documented improved
      survival rates. Since no first line regimen has demonstrated compelling superiority in the
      management of advanced stage ovarian carcinoma, the combination of paclitaxel, carboplatin,
      and metformin is of particular interest given the triplet's prospect for achieving increased
      synergy without compromising patient tolerability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II, open-label, non-randomized, pilot study assessing the safety, toxicity, and
      progression free survival of advanced stage ovarian carcinoma patients who underwent
      treatment with paclitaxel, carboplatin and metformin. An estimated 30 patients will be
      required for this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>The primary outcome of progression free survival will compare the percentage of those who have either progressed or died at 1 year with those who were at risk for at least 1 year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic biomarker evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Glucose (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic biomarker evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Fasting insulin (mIU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic biomarker evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>BMI (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic biomarker evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Urine (mOsm/kg)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Epithelial Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Paclitaxel, carboplatin and metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Metformin (850 mg) Drug: Carboplatin (AUC 5 or 6) Drug: Paclitaxel (80 mg/m2)
The regimen will be administered as a dose dense schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin with standard chemotherapy</description>
    <arm_group_label>Paclitaxel, carboplatin and metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Standard chemotherapy</description>
    <arm_group_label>Paclitaxel, carboplatin and metformin</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Standard chemotherapy</description>
    <arm_group_label>Paclitaxel, carboplatin and metformin</arm_group_label>
    <other_name>Carbo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female Gender

        Age greater than 18 years

        Advanced stage epithelial ovarian, fallopian tube, or primary peritoneal cancer

        Adequate bone marrow function

        ECOG performance score of 2 or greater

        Patients must be able to swallow oral medication.

        Exclusion Criteria:

        Subjects must NOT be taking metformin or have been on metformin in the past 6 months.

        Subjects with a diagnosis of epithelial ovarian, fallopian tube or peritoneal cancers of
        low malignant potential (borderline carcinomas)

        Subjects with concomitant malignancy or a previous malignancy within the past three years,
        melanoma skin cancer excepted
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa N Abaid, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Associates</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa N Abaid, M.D., M.P.H.</last_name>
    <phone>949-642-1361</phone>
    <email>Research@gynoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katrina Lopez, CCRC</last_name>
    <phone>949-642-5165</phone>
    <phone_ext>259</phone_ext>
    <email>Katrinal@gynoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gynecologic Oncology Associates</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Lopez, CCRC</last_name>
      <phone>949-642-5165</phone>
      <phone_ext>259</phone_ext>
      <email>Katrinal@gynoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2015</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared once all data is reviewed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

